ImmunoCellular Therapeutics Ltd.
IMUC.WS
IMUC.WS was delisted on the 16th of October, 2018.
0 hedge funds and large institutions have $0 invested in ImmunoCellular Therapeutics Ltd. in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $1K → $0 (-$1K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| – | -$1K | -14,139 | Closed |
|
IMUC.WS Hedge Fund Activity: Q4 2018 in Review
0 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q4 2018, worth a combined $0 — down 100% from $1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IMUC.WS and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $1K sold.
- 0 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q4 2018, down from 2 in Q3 2018.
- Funds reported $0 of ImmunoCellular Therapeutics Ltd. stock for Q4 2018, down 100% quarter-over-quarter.
- 0 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q4 2018 and 2 closed out, a net change of -2 holders.
- The largest ImmunoCellular Therapeutics Ltd. seller in Q4 2018 was Citadel Advisors, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2018.